Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines (Businesswire) - Apr 24, 2024 - "Endeavor BioMedicines, Inc...announced the closing of a $132.5 million Series C financing, including the conversion of a $5 million convertible instrument....Endeavor will use the financing proceeds to advance the clinical development of ENV-101, its lead candidate for...to advance ENV-501, a human epidermal growth factor 3 (HER3) antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors through clinical proof-of-concept studies....Endeavor intends to initiate a Phase 1/2 trial of ENV-501 in 2024."
Financing • New P1/2 trial • Oncology • Solid Tumor
|